PimedBio
ABOUT US
About US
We create new treatments
based on cutting-edge approaches.
창업이야기
연혁
리더십
협력사
찾아오시는길
PLATFORM
Platform
We create new treatments
based on cutting-edge approaches.
Platform Technology
PIPELINE
Pipeline
We create new treatments
based on cutting-edge approaches.
OVERVIEW
Oncology
IMMUNOLOGY
PR
PR
We create new treatments
based on cutting-edge approaches.
언론보도
공지사항
IR
CAREER
CAREER
We create new treatments
based on cutting-edge approaches.
Recruitment notice
Join us
KR
EN
About Us
창업이야기
연혁
리더십
협력사
찾아오시는길
Platform
Platform technology
Pipeline
Overview
Oncology
PMB212(Cancer stemness blocking agent)
Inhibitor-drug conjugates: IDC
The 3rd-Generation Immuno-oncology therapeutics
Immunology
PMB702(Novel IBD therapeutics)
PR
언론보도
공지사항
IR
Creer
Recruitment notice
Join Us
Instagram
Twitter
Facebook
PR
Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
언론보도
공지사항
IR
PR
공지사항
공지사항
Notice
2025.03.12
제 8회 정기 주주총회
Notice
2024.03.13
제 7회 정기주주총회
Notice
2023.12.19
파이메드바이오_2023 국가신약개발사업 10대 우수과제 선정
Notice
2023.10.26
임시 주주총회 안내
Notice
2023.03.14
제6기 정기주주총회
Notice
2022.03.15
제5기 정기주주총회
Notice
2022.02.08
케이메디허브와 위탁생산 및 개발 관련 업무협약식(MOU)
Notice
2022.02.07
임시주주총회
1
